Cidara Therapeutics to Participate in the Raymond James Human Health Innovation Conference

Rhea-AI Summary

Cidara Therapeutics (Nasdaq: CDTX) announced that CEO Jeffrey Stein and CFO James Levine will participate in investor meetings at the Raymond James Human Health Innovation Conference from June 21-23, 2021. The company focuses on developing long-acting therapeutics to address serious fungal and viral infections, with notable products including the antifungal candidate rezafungin and antiviral candidates from its Cloudbreak platform. Cidara is headquartered in San Diego, California.

SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, and James Levine, Chief Financial Officer, will participate in investor meetings at the Raymond James Human Health Innovation Conference, being held virtually June 21-23, 2021.

About Cidara Therapeutics
Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to AVCs for the prevention and treatment of influenza and other viral diseases from Cidara’s proprietary Cloudbreak^® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

MEDIA CONTACT:
Patrick Bursey
LifeSci Communications
(203) 430-9545
pbursey@lifescicomms.com

FAQ

When will Cidara Therapeutics participate in the Raymond James Human Health Innovation Conference?

Cidara Therapeutics will participate in the Raymond James Human Health Innovation Conference from June 21-23, 2021.

Who from Cidara Therapeutics will speak at the conference?

CEO Jeffrey Stein and CFO James Levine will represent Cidara Therapeutics at the conference.

What is the focus of Cidara Therapeutics?

Cidara Therapeutics focuses on developing long-acting therapeutics for serious fungal and viral infections.

What is Cidara's lead antifungal candidate?

Cidara's lead antifungal candidate is rezafungin.

What is the Cloudbreak platform used by Cidara?

The Cloudbreak platform is used by Cidara for developing antiviral candidates for influenza and other viral diseases.